Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.
Objective
We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.
Methods
A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.
Results
52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.
Conclusion
Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
ThompsonLDWienekeJAMiettinenM. Sinonasal tract and nasopharyngeal melanomas: A clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol. 2003;27(5):594–611. doi:https://doi.org/10.1097/00000478-200305000-00004
KlebanerDSaddawi-KonefkaRFinegershA, et al.Immunotherapy in sinonasal melanoma: Treatment patterns and outcomes compared to cutaneous melanoma. Int Forum Allergy Rhinol.2020;10(9):1087–1095. doi:https://doi.org/10.1002/alr.22628
4.
EdgeSBComptonCC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:https://doi.org/10.1245/s10434-010-0985-4
5.
SalariBForemanRKEmerickKSLawrenceDPDuncanLM. Sinonasal mucosal melanoma: An update and review of the literature. Am J Dermatopathol.2022;44(6):424–432. doi:https://doi.org/10.1097/dad.0000000000002157
6.
RobertCLongGVBradyB, et al.Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med.2015;372(4):320–330. doi:https://doi.org/10.1056/NEJMoa1412082
7.
RibasAPuzanovIDummerR, et al.Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918. doi:https://doi.org/10.1016/s1470-2045(15)00083-2
8.
EggermontAMChiarion-SileniVGrobJJ, et al.Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med.2016;375(19):1845–1855. doi:https://doi.org/10.1056/NEJMoa1611299
9.
EggermontAMMBlankCUMandalaM, et al.Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Eng J Med. 2018;378(19):1789–1801. doi:https://doi.org/10.1056/NEJMoa1802357
10.
CoitDGThompsonJAAlbertiniMR, et al.Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(4):367–402. doi:https://doi.org/10.6004/jnccn.2019.0018
11.
JohnsonBJGuoRMooreEJ, et al.Sinonasal mucosal melanoma: An analysis of treatment-related adverse events and associated factors. Int Forum Allergy Rhinol.2023;13(6):1037-1041. doi:https://doi.org/10.1002/alr.23118
12.
ChangCYParkHMaloneDC, et al.Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis. JAMA Netw Open. 2020;3(3):e201611. doi:https://doi.org/10.1001/jamanetworkopen.2020.1611
13.
HodiFSChesneyJPavlickAC, et al.Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–1568. doi:https://doi.org/10.1016/s1470-2045(16)30366-7
14.
GantiARamanAShayA, et al.Treatment modalities in sinonasal mucosal melanoma: A national cancer database analysis. Laryngoscope. 2020;130(2):275–282. doi:https://doi.org/10.1002/lary.27995
15.
AbiriAYasakaTMLehrichBM, et al.Adjuvant therapy and prognosticators of survival in head and neck mucosal melanoma. Laryngoscope. 2022;132(3):584–592. doi:https://doi.org/10.1002/lary.29807
16.
GuoRJenkinsSMJohnsonBJReedKKronemanTChobyG. Sinonasal mucosal melanoma: Role of tumor proliferative indices and pathological factors in survival. Laryngoscope. 2022;132(12):2350–2358. doi:https://doi.org/10.1002/lary.30240
17.
TheurichSRothschildSIHoffmannM, et al.Local tumor treatment in combination with systemic Ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res. 2016;4(9):744–754. doi:https://doi.org/10.1158/2326-6066.Cir-15-0156
ChaoTNKuanECTongCCL, et al.Surgical treatment of sinonasal mucosal melanoma in patients treated with systemic immunotherapy. J Neurol Surg Part B Skull Base. 2021;82(Suppl 3):e148–e154. doi:https://doi.org/10.1055/s-0040-1701219
20.
Vázquez-MonteroLde la GalaMde la Cruz-MerinoL. Nivolumab plus ipilimumab in metastatic melanoma: A critical appraisal focused on specific subpopulations. Front Oncol. 2023;13:1187840. doi:https://doi.org/10.3389/fonc.2023.1187840
21.
LarkinJChiarion-SileniVGonzalezR, et al.Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med.2015;373(1):23–34. doi:https://doi.org/10.1056/NEJMoa1504030
22.
PostowMAChesneyJPavlickAC, et al.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med.2015;372(21):2006–2017. doi:https://doi.org/10.1056/NEJMoa1414428
